ArticleMicrobiology spectrum2023
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Effect of Biosynthesized Gold and Silver Nanoparticles UsingAntibiotics (Basel, Switzerland) · 2026Article
- Mapping the knowledge landscape ofFrontiers in cellular and infection microbiology · 2026Review
- Enhanced antibacterial properties of amoxicillin-loaded silver nanoparticles against Methicillin-resistantPeerJ · 2026Article
- Recent advances in metallic nanostructure-based photothermal therapy in the management of cancer metastasis.Medical oncology (Northwood, London, England) · 2025Review
- Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Insights into the pharmaceutical properties of green fabricated Iron oxide nanoparticles.Scientific reports · 2025Article
- Potential Use of Cefiderocol and Nanosilver in Wound Dressings to Control Multidrug-Resistant Gram-Negative Bacteria.Molecules (Basel, Switzerland) · 2025Article
- Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health.RSC advances · 2025Review
- Silver Nanoparticles and Antibiotics: A Promising Synergistic Approach to Multidrug-Resistant Infections.Microorganisms · 2025Review
- Silver nanoparticles as next-generation antimicrobial agents: mechanisms, challenges, and innovations against multidrug-resistant bacteria.Frontiers in cellular and infection microbiology · 2025Review
- Evaluating Anti-Journal of pharmacy & bioallied sciences · 2024Article
- Excellent antibacterial and anti-inflammatory efficacy of amoxicillin by AgNPs and their conjugates synthesized usingHeliyon · 2024Article
- Biogenically synthesized green silver nanoparticles exhibit antimalarial activity.Discover nano · 2024Article
- Article
- Green fabrication of ZnO nanoparticles via spirulina platensis and its efficiency against biofilm forming pathogens.Microbial cell factories · 2024Article
- Advances in silver nanoparticles: a comprehensive review on their potential as antimicrobial agents and their mechanisms of action elucidated by proteomics.Frontiers in microbiology · 2024Review
- Antimicrobial resistance ofFrontiers in microbiology · 2024Review
- Recent advances in nanoantibiotics against multidrug-resistant bacteria.Nanoscale advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In view of the current increase and spread of antimicrobial resistance (AMR), there is an urgent need to find new strategies to combat it. This study had two aims. First, we synthesized highly monodispersed silver nanoparticles (AgNPs) of approximately 17 nm, and we functionalized them with mercaptopoly(ethylene glycol) carboxylic acid (mPEG-COOH) and amikacin (AK). Second, we evaluated the antibacterial activity of this treatment (AgNPs_mPEG_AK) alone and in combination with hyperthermia against planktonic and biofilm-growing strains. AgNPs, AgNPs_mPEG, and AgNPs_mPEG_AK were characterized using a suite of spectroscopy and microscopy methods. Susceptibility to these treatments and AK was determined after 24 h and over time against 12 clinical multidrug-resistant (MDR)/extensively drug-resistant (XDR) isolates of Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The efficacy of the treatments alone and in combination with hyperthermia (1, 2, and 3 pulses at 41°C to 42°C for 15 min) was tested against the same planktonic strains using quantitative culture and against one P. aeruginosa strain growing on silicone disks using confocal laser scanning microscopy. The susceptibility studies showed that AgNPs_mPEG_AK was 10-fold more effective than AK alone, and bactericidal efficacy after 4, 8, 24, or 48 h was observed against 100% of the tested strains. The combination of AgNPs_mPEG_AK and hyperthermia eradicated 75% of the planktonic strains and exhibited significant reductions in biofilm formation by P. aeruginosa in comparison with the other treatments tested, except for AgNPs_mPEG_AK without hyperthermia. In conclusion, the combination of AgNPs_mPEG_AK and hyperthermia may be a promising therapy against MDR/XDR and biofilm-producing strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.